Comprehensive Urologic Care

Lake Barrington, Illinois 60010

4 studies enrolling now · 15 studies all time

What they study most

Adenocarcinoma of the Prostate, Androgen Resistant Prostatic Cancer, BPH With Symptomatic Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Bladder Cancer, Kidney Calculi; Ureteral Calculi, Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, NMIBC, Non-muscle Invasive Bladder Cancer, Prostate Cancer, Treatment of Patients Suffering From Overactive Bladder (OAB)

Studies at this site

• Study of ORIC-944 in Patients With Metastatic Prostate Cancer — Recruiting now
• Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer — Recruiting now
• Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial — Recruiting now
• Optilume™ BPH Catheter System in Men With Symptomatic BPH — Running, not enrolling
• ProVee Urethral Expander System IDE Study (ProVIDE) — Running, not enrolling
• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
• ProVIDE II Bridging Study — Running, not enrolling
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate — Completed
• ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer — Available (expanded access)
• Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI) — Running, not enrolling
• BlueWind RENOVA iStim™ System for the Treatment of OAB — Completed
• Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer — Completed
• A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — Stopped early
• Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent — Stopped early
• A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease — Stopped early